Related Experiment Video
Updated: Jul 28, 2025

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
Published on: August 28, 2020
Adherence to Overactive Bladder Syndrome Treatments Recent Developments and Future Perspectives
Dudley Robinson1, Miriam O'Kane1, Linda Cardozo1
1Department of Urogynaecology, King's College Hospital, London, UK.
Overactive bladder (OAB) management involves conservative measures and medications like antimuscarinics and mirabegron. This review focuses on patient adherence, treatment efficacy, and options for refractory OAB.
Area of Science:
- Urology
- Pharmacology
- Patient Health
Background:
- Overactive bladder (OAB) significantly impacts Health-Related Quality of Life (HRQoL).
- Conservative measures are initial OAB treatments, but many patients require pharmacotherapy.
- Antimuscarinics are common OAB drugs, yet poor adherence occurs due to side effects and limited efficacy.
Purpose of the Study:
- To review OAB management strategies, emphasizing patient adherence (compliance and persistence).
- To evaluate antimuscarinics and the B3-agonist mirabegron for OAB treatment.
- To explore management of refractory OAB and future treatment developments.
Main Methods:
- Literature review of OAB management strategies.
- Focus on patient adherence, including compliance and persistence.
- Analysis of antimuscarinic and mirabegron efficacy and barriers.
Main Results:
- Antimuscarinics are widely used but face adherence challenges.
- Mirabegron offers an alternative, but its adoption and efficacy barriers exist.
- Refractory OAB requires specific management approaches.
Conclusions:
- Optimizing patient adherence is crucial for effective OAB management.
- Understanding barriers to antimuscarinic and mirabegron use is key.
- Further research into refractory OAB and novel therapies is warranted.
Related Concept Videos
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Urinary Tract Calculi III: Medical Management
Urinary Bladder
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Irritable Bowel Syndrome III: Medical and Nursing Management

